Industry can play role in educating consumers about new drugs' risks and benefits

09/27/2011

Results of a recent study show that consumers generally prefer new drugs over older drugs, without fully understanding the newer drugs' risks and benefits. These findings demonstrate that the FDA's efforts to inform the public about its approval process are insufficient. "This study confirms that the public lacks understanding of what FDA approval constitutes," pharma industry consultant Wayne Pines noted. Industry can play a role in consumer education as well, according to Peter Pitts, president and co-founder of the Center for Medicine in the Public Interest. Read more.

View Full Article in:

http://www.cohealthcom.org/2011/09/21/gaps-in-public-understanding-of-new-drugs-...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI